"Meningeal Carcinomatosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation.
| Descriptor ID |
D055756
|
| MeSH Number(s) |
C04.588.614.250.580.150 C10.551.240.500.150
|
| Concept/Terms |
Meningeal Carcinomatosis- Meningeal Carcinomatosis
- Carcinomatoses, Meningeal
- Carcinomatosis, Meningeal
- Meningeal Carcinomatoses
- Carcinomatous Meningitis
- Carcinomatous Meningitides
- Meningitides, Carcinomatous
- Meningitis, Carcinomatous
- Leptomeningeal Carcinomatosis
- Carcinomatoses, Leptomeningeal
- Carcinomatosis, Leptomeningeal
- Leptomeningeal Carcinomatoses
|
Below are MeSH descriptors whose meaning is more general than "Meningeal Carcinomatosis".
Below are MeSH descriptors whose meaning is more specific than "Meningeal Carcinomatosis".
This graph shows the total number of publications written about "Meningeal Carcinomatosis" by people in this website by year, and whether "Meningeal Carcinomatosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Meningeal Carcinomatosis" by people in Profiles.
-
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Dec; 8:e2400373.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Management of Leptomeningeal Disease From Solid Tumors. Oncology (Williston Park). 2016 08; 30(8):724-30.
-
Rapidly progressive dementia with hypoglycorrhachia. J Clin Neurosci. 2015 Oct; 22(10):1685-7.
-
Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities. J Clin Neurosci. 2015 Apr; 22(4):632-7.
-
Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Dis Esophagus. 2015 Nov-Dec; 28(8):772-81.
-
Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J Clin Neurosci. 2014 Jul; 21(7):1250-1.